We now show evidence from patient serum that circulating ligands for the c-Met pathway as well as the EGFR pathway are frequently high in subjects with lung cancer compared to controls, that signaling via these two pathways is redundant in lung cancer cells in vitro, and that targeting these two pathways simultaneously in our carcinogenesis animal model results in increased anti-tumor effects. The gene discussed is MET; the disease is lung carcinoma.